Follicular Lymphoma

Use an adequate tissue specimen that permits assessment of nodal architecture, cytology, and immunophenotype. Excisional biopsy is preferred when feasible because architecture may be necessary to establish lymphoma in lesions composed of well-differentiated lymphocytes; needle samples can provide insufficient architectural information. ScienceDirectScienceDirectImmunoblast - an overview | ScienceDirect Topics

Separate grade 1-2 and grade 3A FL from grade 3B FL at diagnosis because grade 3B was excluded from a major frontline FL trial and should not automatically be managed under an indolent-FL treatment framework. clinicaltrialsclinicaltrialsStudy Details | NCT01650701 | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma | ClinicalTrials.gov Grade assignment is clinically consequential, but reproducibility between low-grade FL and grade 3A can be challenging. ScienceDirectScienceDirectEvaluating Novel PET-CT Functional Parameters TLG and ...

At progression, do not assume recurrent indolent FL when there is discordant clinical behavior or a new highly FDG-avid site. Transformed indolent lymphoma can present on PET/CT as newly increased nodal avidity or new FDG-avid lesions in other organs; biopsy the most clinically suspicious accessible lesion before selecting therapy intended for relapsed indolent FL. ScienceDirectScienceDirect6 Imaging in follicular NHL

Use FDG PET/CT as the preferred imaging modality for staging and response assessment in FL. PET/CT is more sensitive than standard CT, can improve identification of truly limited-stage disease, and helps distinguish viable tumor from residual fibrotic tissue after treatment. ScienceDirectScienceDirectIs it time for PET-guided therapy in follicular lymphoma?

Do not rely on PET/CT to exclude marrow involvement. PET/CT has relatively low sensitivity for FL marrow disease, so a negative scan does not establish marrow-negative disease when marrow status would alter staging or management. ScienceDirectScienceDirectFDG PET-CT in follicular lymphoma: a case-based evidence ...

For patients being considered for limited-stage treatment, rigorously establish stage with imaging and bone marrow biopsy. In PET-era outcome data, patients staged with marrow biopsy plus CT or PET/CT had superior progression-free survival compared with less rigorously staged cohorts, supporting careful confirmation before labeling disease as stage I/II. ScienceDirectScienceDirectOutcomes of stage I/II follicular lymphoma in the PET era

Observation remains an acceptable initial strategy for low-grade FL when disease is not creating a clinical indication for therapy. This approach avoids immediate treatment toxicity in a disease course where patients commonly require multiple treatments over time. ASH+1ASHIs watch and wait still acceptable for patients with low-grade ...NatureFollicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups | Blood Cancer Journal

When initiating systemic frontline treatment, select the regimen according to disease burden, treatment goals, comorbidity, and anticipated long-term sequence rather than assuming one induction strategy fits all patients. A phase III trial compared rituximab-lenalidomide with rituximab-chemotherapy followed by rituximab in previously untreated FL and evaluated complete response, progression-free survival, time to next treatment, overall survival, adverse events, and quality of life. clinicaltrialsclinicaltrialsStudy Details | NCT01650701 | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma | ClinicalTrials.gov

For patients responding to rituximab-containing chemotherapy, rituximab maintenance for 2 years improved progression-free survival in high-tumor-burden FL in the PRIMA randomized trial; long-term follow-up reported that approximately half of maintenance-treated patients remained progression-free at 10 years. NatureNatureFollicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups | Blood Cancer Journal Balance this disease-control benefit against continued anti-CD20 exposure and the patient's anticipated subsequent treatment needs.

Define early symptomatic progression as relapse within 24 months after completion of first-line therapy (POD24). This interval identifies a clinically important high-risk subgroup and should trigger reassessment for transformation, prior treatment refractoriness, fitness for intensive strategies, and suitability for T-cell–engaging therapy or cellular therapy sequencing. ASH+1ASHThe POD24 challenge: where do we go from here for early ...ESMOFollicular Lymphoma: Relapsed or Refractory Disease Management in Second Line

For rituximab-refractory FL with early progression, obinutuzumab-bendamustine is an evidence-supported option. However, if a T-cell–engaging therapy is anticipated later, avoid bendamustine because its long-term immunosuppression may compromise that sequence. ESMOESMOFollicular Lymphoma: Relapsed or Refractory Disease Management in Second Line

For lenalidomide-naive early relapse, rituximab-lenalidomide is an option. ESMO also lists rituximab-lenalidomide-tafasitamab and rituximab-lenalidomide-epcoritamab for lenalidomide-naive early progression; the epcoritamab combination is FDA approved but not EMA approved. ESMOESMOFollicular Lymphoma: Relapsed or Refractory Disease Management in Second Line

For younger fit patients with early POD and chemosensitive relapse, consider autologous stem-cell transplantation as consolidation. This requires establishing chemosensitivity and excluding transformed disease before proceeding. ESMO+1ESMOFollicular Lymphoma: Relapsed or Refractory Disease Management in Second LineScienceDirect6 Imaging in follicular NHL

After treatment, use PET/CT response assessment to distinguish metabolically active disease from residual fibrotic tissue. A negative PET/CT after treatment has strong independent prognostic value for progression-free and overall survival, particularly in high-tumor-burden FL. ScienceDirectScienceDirectIs it time for PET-guided therapy in follicular lymphoma?

Do not use interim PET/CT as a routine treatment-adaptation tool. Although interim PET may add prognostic information beyond FLIPI and FLIPI-2, its role in directing therapy remains unsettled. ScienceDirectScienceDirectPrognostic value of interim PET-CT in follicular lymphoma

At clinical or radiographic progression, repeat PET/CT when the pattern could alter management and biopsy a newly or disproportionately avid lesion. The key surveillance failure is missing transformation and continuing an indolent-FL pathway without renewed tissue confirmation. ScienceDirectScienceDirect6 Imaging in follicular NHL